Literature DB >> 24932905

Application of a prediction model for the progression of rheumatoid arthritis in patients with undifferentiated arthritis.

Ana Arana-Guajardo1, Lorena Pérez-Barbosa2, David Vega-Morales1, Janett Riega-Torres1, Jorge Esquivel-Valerio1, Mario Garza-Elizondo1.   

Abstract

INTRODUCTION: Different prediction rules have been applied to patients with undifferentiated arthritis (UA) to identify those that progress to rheumatoid arthritis (RA). The Leiden Prediction Rule (LPR) has proven useful in different UA cohorts.
OBJECTIVE: To apply the LPR to a cohort of patients with UA of northeastern Mexico.
METHODS: We included 47 patients with UA, LPR was applied at baseline. They were evaluated and then classified after one year of follow-up into two groups: those who progressed to RA (according to ACR 1987) and those who did not.
RESULTS: 43% of the AI patients developed RA. In the RA group, 56% of patients obtained a score ≤ 6 and only 15% ≥ 8. 70% who did not progress to RA had a score between 6 and ≤ 8. There was no difference in median score of LPR between groups, p=0.940.
CONCLUSION: Most patients who progressed to RA scored less than 6 points in the LPR. Unlike what was observed in other cohorts, the model in our population did not allow us to predict the progression of the disease.
Copyright © 2013 Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Artritis indiferenciada; Artritis reumatoide; Community Oriented Program for the Control of the Rheumatic Diseases; Diagnosis; Diagnóstico; Poliartritis; Polyarthritis; Programa Comunitario Orientado al Control de Enfermedades Reumáticas; Rheumatoid arthritis; Undifferentiated arthritis

Mesh:

Year:  2014        PMID: 24932905     DOI: 10.1016/j.reuma.2014.01.007

Source DB:  PubMed          Journal:  Reumatol Clin        ISSN: 1699-258X


  6 in total

1.  Do rheumatologists know how to squeeze? Evaluations of Gaenslen´s maneuver.

Authors:  David Vega-Morales; Jorge Antonio Esquivel-Valerio; Mario Alberto Garza-Elizondo
Journal:  Rheumatol Int       Date:  2015-08-29       Impact factor: 2.631

2.  Increased detection of latent tuberculosis by tuberculin skin test and booster phenomenon in early rheumatoid arthritis patients.

Authors:  L Pérez-Barbosa; J A Esquivel-Valerio; A C Arana-Guajardo; D Vega-Morales; J Riega-Torres; M A Garza-Elizondo
Journal:  Rheumatol Int       Date:  2015-03-14       Impact factor: 2.631

3.  The earlier, the better or the worse? Towards accurate management of patients with arthralgia at risk for RA.

Authors:  Annette van der Helm-van Mil; Robert B M Landewé
Journal:  Ann Rheum Dis       Date:  2020-01-08       Impact factor: 19.103

4.  Anti-cyclic citrullinated peptide antibody predicts the development of rheumatoid arthritis in patients with undifferentiated arthritis.

Authors:  Chun Li; Yan Zhang; Hui Song; Jie Gao; Dong-Bao Zhao; Qi Zhu; Dong-Yi He; Li Wang; Xiang-Pei Li; Xu-Dong Liu; Wei-Guo Xiao; Xin-Yu Wu; Hua-Xiang Wu; Wei Tu; Shao-Xian Hu; Xin Wang; Zhi-Jun Li; Zhi-Min Lu; Zhan-Yun Da; Bo Liang; Xiao-Min Liu; Jin-Wei Zhao; Ling Li; Feng Han; Wu-Fang Qi; Wei Wei; Xu Ma; Zhen-Bin Li; Gui-Min Zheng; Feng-Xiao Zhang; Yi Li; You-Lian Wang; Guang-Hui Ling; Jin-Wei Chen; Xiao-Qiang Hou; Jing Zhang; Qing-Ping Chen; Chang-Lian Liu; Yan Zhang; Jia-Shun Zeng; Qing-Hua Zou; Yong-Fei Fang; Yin Su; Zhan-Guo Li
Journal:  Chin Med J (Engl)       Date:  2019-12-20       Impact factor: 2.628

5.  Establishment of a clinical diagnostic model for gouty arthritis based on the serum biochemical profile: A case-control study.

Authors:  Shang Lyu; Ruowen Ding; Shilin Yang; Wanyuan Chen; Yi Rao; Hui OuYang; Peng Liu; Yulin Feng
Journal:  Medicine (Baltimore)       Date:  2021-04-23       Impact factor: 1.817

Review 6.  Microbiome-miRNA interactions in the progress from undifferentiated arthritis to rheumatoid arthritis: evidence, hypotheses, and opportunities.

Authors:  Haifeng Lu; Yujun Yao; Jiezuan Yang; Hua Zhang; Lanjuan Li
Journal:  Rheumatol Int       Date:  2021-04-15       Impact factor: 2.631

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.